IRADIMED CORP (IRMD) Form 10-Q — Jul 31, 2026
For the quarter ended June 30, 2026, revenue was flat at $20.5 million compared to the prior year, while net income decreased to $5.2 million. The decline in profitability was driven by a gross margin contraction to 74%, attributed to initial production inefficiencies on new product manufacturing. However, for the six-month period, revenue increased 6% to $42.4 million and net income grew 5.5% to $11.0 million. The balance sheet remains robust with cash and cash equivalents increasing 15% to $59.1 million.
Key figures
- Eps
- 0.41
- Revenue
- 20466000
- Net Income
- 5218000
- Cash Position
- 59080000
- Shares Outstanding
- 12786740
Price after filing
Close on the filing date to close N calendar days later (from $94.26). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.